FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763035609> ?p ?o ?g. }

• W2763035609 endingPage "59.e6" @default.
• W2763035609 startingPage "50" @default.
• W2763035609 abstract "Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although the disease can be kept under control using BCR/ABL1 tyrosine kinase inhibitors (TKIs) in most cases, some patients relapse or have resistant disease, so there is a need to identify new therapeutic targets in this malignancy. Recent data suggest that leukemic SCs (LSCs) in CML display the stem-cell (SC)-mobilizing cell surface enzyme dipeptidyl-peptidase IV (DPPIV = CD26) in an aberrant manner. In the present study, we analyzed the effects of the DPPIV blocker vildagliptin as single agent or in combination with the BCR/ABL1 TKI imatinib or nilotinib on growth and survival of CML LSCs in vitro and on LSC engraftment in an in vivo xenotransplantation nonobese diabetic SCID-IL-2Rγ-/- (NSG) mouse model. We found that nilotinib induces apoptosis in CML LSCs and inhibits their engraftment in NSG mice. In contrast, no substantial effects were seen with imatinib or vildagliptin. Nevertheless, vildagliptin was found to reduce the mobilization of CML LSCs from a stroma cell layer consisting of mouse fibroblasts in an in vitro co-culture model, suggesting reduced disease expansion. However, although vildagliptin and nilotinib produced cooperative effects in individual experiments, overall, no significant effects of coadministered vildagliptin over nilotinib or imatinib treatment alone were seen on the engraftment of CML cells in NSG mice. Gliptins may be interesting drugs in the context of CML and nilotinib therapy, but our preclinical studies did not reveal a major cooperative effect of the drug-combination vildagliptin + nilotinib on engraftment of CML cells in NSG mice." @default.
• W2763035609 created "2017-10-20" @default.
• W2763035609 creator A5001718541 @default.
• W2763035609 creator A5006306448 @default.
• W2763035609 creator A5018477953 @default.
• W2763035609 creator A5026124941 @default.
• W2763035609 creator A5028300912 @default.
• W2763035609 creator A5032243711 @default.
• W2763035609 creator A5033323842 @default.
• W2763035609 creator A5040052716 @default.
• W2763035609 creator A5052025914 @default.
• W2763035609 creator A5059262225 @default.
• W2763035609 creator A5064730399 @default.
• W2763035609 creator A5086011150 @default.
• W2763035609 date "2018-01-01" @default.
• W2763035609 modified "2023-10-16" @default.
• W2763035609 title "Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia" @default.
• W2763035609 cites W12745932 @default.
• W2763035609 cites W1964358866 @default.
• W2763035609 cites W1964505039 @default.
• W2763035609 cites W1970504379 @default.
• W2763035609 cites W1972809192 @default.
• W2763035609 cites W1975645428 @default.
• W2763035609 cites W1976515482 @default.
• W2763035609 cites W1979050260 @default.
• W2763035609 cites W1987930421 @default.
• W2763035609 cites W1989771583 @default.
• W2763035609 cites W1992382947 @default.
• W2763035609 cites W1994309500 @default.
• W2763035609 cites W1996346809 @default.
• W2763035609 cites W1998593414 @default.
• W2763035609 cites W2012153991 @default.
• W2763035609 cites W2016656445 @default.
• W2763035609 cites W2024712102 @default.
• W2763035609 cites W2035197415 @default.
• W2763035609 cites W2037905760 @default.
• W2763035609 cites W2040033475 @default.
• W2763035609 cites W2040396943 @default.
• W2763035609 cites W2050184823 @default.
• W2763035609 cites W2052202516 @default.
• W2763035609 cites W2054251966 @default.
• W2763035609 cites W2060351783 @default.
• W2763035609 cites W2061741321 @default.
• W2763035609 cites W2063700839 @default.
• W2763035609 cites W2067226260 @default.
• W2763035609 cites W2067292278 @default.
• W2763035609 cites W2076372887 @default.
• W2763035609 cites W2086344594 @default.
• W2763035609 cites W2101246901 @default.
• W2763035609 cites W2107503279 @default.
• W2763035609 cites W2112817157 @default.
• W2763035609 cites W2115524556 @default.
• W2763035609 cites W2115626434 @default.
• W2763035609 cites W2122224021 @default.
• W2763035609 cites W2136752386 @default.
• W2763035609 cites W2137984061 @default.
• W2763035609 cites W2146317534 @default.
• W2763035609 cites W2147109509 @default.
• W2763035609 cites W2177783313 @default.
• W2763035609 cites W2213547035 @default.
• W2763035609 cites W2285217986 @default.
• W2763035609 cites W2314938037 @default.
• W2763035609 cites W2329648702 @default.
• W2763035609 cites W2333005287 @default.
• W2763035609 cites W2343680173 @default.
• W2763035609 cites W2560023695 @default.
• W2763035609 cites W2567414578 @default.
• W2763035609 cites W2580232087 @default.
• W2763035609 cites W2607524091 @default.
• W2763035609 cites W4237872556 @default.
• W2763035609 cites W551869 @default.
• W2763035609 doi "https://doi.org/10.1016/j.exphem.2017.09.012" @default.
• W2763035609 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7115814" @default.
• W2763035609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29031704" @default.
• W2763035609 hasPublicationYear "2018" @default.
• W2763035609 type Work @default.
• W2763035609 sameAs 2763035609 @default.
• W2763035609 citedByCount "14" @default.
• W2763035609 countsByYear W27630356092019 @default.
• W2763035609 countsByYear W27630356092020 @default.
• W2763035609 countsByYear W27630356092021 @default.
• W2763035609 countsByYear W27630356092022 @default.
• W2763035609 countsByYear W27630356092023 @default.
• W2763035609 crossrefType "journal-article" @default.
• W2763035609 hasAuthorship W2763035609A5001718541 @default.
• W2763035609 hasAuthorship W2763035609A5006306448 @default.
• W2763035609 hasAuthorship W2763035609A5018477953 @default.
• W2763035609 hasAuthorship W2763035609A5026124941 @default.
• W2763035609 hasAuthorship W2763035609A5028300912 @default.
• W2763035609 hasAuthorship W2763035609A5032243711 @default.
• W2763035609 hasAuthorship W2763035609A5033323842 @default.
• W2763035609 hasAuthorship W2763035609A5040052716 @default.
• W2763035609 hasAuthorship W2763035609A5052025914 @default.
• W2763035609 hasAuthorship W2763035609A5059262225 @default.
• W2763035609 hasAuthorship W2763035609A5064730399 @default.
• W2763035609 hasAuthorship W2763035609A5086011150 @default.
• W2763035609 hasBestOaLocation W27630356092 @default.
• W2763035609 hasConcept C121608353 @default.

• next